Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used for the first-line treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. Currently, five EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) are clinically available in the US as well as in Japan. Following the FLAURA trial, which demonstrated the superiority of front-line osimertinib in both progression-free and overall survival compared with gefitinib/erlotinib, many physicians prefer to use osimertinib as a front-line treatment [1].

Source: Lung Cancer - February 17, 2021 Category: Cancer & Oncology Authors: Shuta Ohara, Kenichi Suda, Toshio Fujino, Akira Hamada, Takamasa Koga, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi Source Type: research